Clinical Knowledge Summary: Autologous conditioned serum and orthobiologics (Longevity Medicine)

1. Scope

What is covered:

– Autologous conditioned serum (ACS) — whole blood incubated with medical-grade glass beads to enrich interleukin-1 receptor antagonist (IL-1Ra) and anti-inflammatory cytokines, then re-injected (brand examples: Orthokine/Regenokine).[1]

– Related autologous peripheral blood-derived orthobiologics (APBOs): platelet-rich plasma (PRP), platelet lysate, plasma rich in growth factors (PRGF), autologous protein solution (APS).[2]

– Cell-based and vesicle products touched on for context only: mesenchymal stromal cells (MSCs), bone marrow aspirate concentrate (BMAC), exosomes/extracellular vesicles (EVs).[3][4]

What is not covered: heterochronic parabiosis, therapeutic plasma exchange, young plasma transfusion, cosmetic (“vampire”) facial applications, and gene therapy beyond brief mention.

Framing: The robust human evidence for ACS/orthobiologics is confined to symptomatic musculoskeletal disease (chiefly knee osteoarthritis and tendinopathy). There is no high-quality human evidence that any of these products modify ageing biology, mortality, or validated ageing biomarkers. Within a longevity clinic these should be positioned as adjunctive musculoskeletal/functional-preservation interventions, not as anti-ageing therapies. All longevity/”rejuvenation” indications are experimental / mechanistic-plausibility only.

 

2. Background and pathophysiology

Biological rationale (musculoskeletal, human-relevant):

– Osteoarthritis and tendinopathy involve IL-1β–driven catabolism of cartilage and matrix. ACS is designed to deliver supraphysiological IL-1Ra plus IL-4, IL-10, IL-13 and growth factors to interrupt this cascade and support endogenous repair.[1]

– PRP and related products deliver a concentrated pool of platelet-derived growth factors (PDGF, TGF-β, VEGF, IGF-1) intended to modulate local inflammation and anabolism.[3]

Purported longevity mechanisms (NOT established in humans):

– Hallmarks-of-ageing framing (cellular senescence, stem-cell exhaustion, chronic “inflammageing”, altered intercellular communication, mitochondrial dysfunction) is invoked for MSCs, EVs and blood-derived factors.[5][6]

– These links are mechanistic hypotheses; there is no demonstrated effect of ACS or PRP on human lifespan, healthspan, or epigenetic/biological age.

Preclinical subsection (clearly separated — animal/in-vitro only):

– In senescence-accelerated mice, PRP reduced stem-cell senescence markers and was associated with prolonged survival and improved ageing phenotypes. Rodent/animal data only.[7]

– MSCs and MSC/ESC-derived EVs shifted multi-organ “omic” profiles of aged rodents toward younger states; a majority of over-represented miRNAs in ESC-derived EVs target longevity-associated genes.[8]

– MSC/exosome reviews describe modulation of multiple ageing hallmarks in preclinical models.[5]

– These data must not be extrapolated to human clinical benefit.

 

3. Evidence base and grading

Types of evidence available: For ACS specifically — one systematic review/meta-analysis of RCTs and several individual RCTs in knee OA; systematic reviews of autologous IL-1Ra products and shoulder APBOs.[2][9][10] For PRP — multiple RCTs, meta-analyses, and European society consensus documents.[11][12] For cell therapies in ageing/frailty — small early-phase trials only.[13] Longevity endpoints (mortality, ageing biomarkers) are not studied for these products in adequately powered human trials.

GRADE-style certainty by outcome:

Outcome / population	Evidence & certainty	Strength of recommendation	Rationale
ACS for knee OA pain/function (vs saline)	Low–Very low. Meta-analysis: 5 RCTs, n=741; ACS favoured vs all comparators at 6 mo (WOMAC SMD −0.61) but no significant difference vs saline placebo (WOMAC SMD −0.40, 95% CI −0.93 to 0.12); high heterogeneity, RoB concerns[9]	Only in research / conditional at best — do not offer routinely	Downgraded for risk of bias, inconsistency, imprecision
ACS added to intra-articular steroid, knee OA	Low. Single small RCT (n=40) showed added long-term KOOS/pain benefit at 24 wk[14]	Conditional (weak)	Single-centre, small, needs replication
Autologous IL-1Ra products (ACS/APS), knee OA	Low. Systematic review, 3 RCTs + 5 non-comparative (n=592); mixed improvement, safe[10]	Conditional / only in research	Level IV review, indirect
APBOs for shoulder disorders	Very low. Only 6 heterogeneous studies; safe, possible benefit[2]	Only in research	Sparse data, no RCTs for most products
PRP for knee OA (KL 1–3)	Low–Moderate, conflicting. ESSKA consensus regards PRP a valid option for mild–moderate OA[11], [12]; however recent high-quality reviews report no superiority over saline and support recommending against as disease-modifying[15]	Conditional / recommend against as disease-modifying — genuine guideline disagreement	Preserve conflict: society consensus vs recent negative data
Autologous blood/PRP for lateral elbow pain	Low. Cochrane review; evidence inadequate; NICE previously judged evidence inadequate in quantity/quality[16]	Recommend against routine use	High RoB, small trials
MSCs for (physical) frailty	Very low. Phase I/II only; feasible, safe, possibly efficacious[13]	Only in research (clinical trials)	Early-phase, underpowered
Any product for mortality / biological-age reversal	No human evidence	Only in research	Preclinical/mechanistic only[5], [6], [7], [8]

Key honesty point: the single most important finding is that when ACS is compared against saline placebo, the OA benefit is not statistically significant — much of the apparent effect reflects comparison against active comparators, heterogeneity, and placebo response.[9]

 

4. Patient selection and indications

Who might reasonably be considered (musculoskeletal, adjunctive):

– Adults with symptomatic mild-to-moderate knee OA (Kellgren–Lawrence 1–3) who have failed conservative non-injective and/or injective treatment, aged ≤80, wishing to defer surgery.[11][12]

– Adults with chronic tendinopathy or shoulder disorders refractory to standard care, understanding evidence is weak.[2][16]

– Athletic/active individuals seeking functional preservation — must be counselled that benefit for performance or longevity is unproven.

Baseline thresholds: there are no validated biomarker or ageing-clock thresholds that identify responders; selection is clinical and symptom-driven.

Exclusion / high-risk groups:

– Active local or systemic infection, septic arthritis, overlying skin breakdown.

– Active or recent malignancy (theoretical concern with growth-factor/cell products — specialist input).

– Significant coagulopathy or therapeutic anticoagulation (procedural bleeding risk).

– KL grade 4 / end-stage OA (inappropriate for PRP by consensus).[12]

– Frail older multimorbid patients: no evidence of benefit; cell therapies remain research-only.[13]

Regulatory and ethical status (UK):

– ACS and PRP prepared and re-administered as a single-patient autologous point-of-care product generally fall outside licensed-medicine pathways, but this is a regulatory grey area — practitioners must confirm current MHRA/HTA status and any Human Tissue Authority licensing applicable to processing.

– All use for longevity/anti-ageing indications is off-label and not guideline-supported; NICE has judged autologous blood/PRP evidence for tendinopathy inadequate.[16]

– Allogeneic MSCs, exosomes and “stem-cell” products are not licensed for these indications and should be only within clinical trials.[4][5]

– Practice should proceed only as adjunctive care with rigorous informed consent, ideally within a registry or trial framework.

 

5. Assessment and baseline work-up

History and examination:

– Confirm diagnosis and symptom duration; document prior treatments (analgesics, physiotherapy, steroid/HA injections, surgery).

– Screen for red flags: infection, inflammatory arthropathy, malignancy, mechanical locking.

– Medication review (anticoagulants/antiplatelets, immunosuppressants, systemic steroids).

Validated scoring tools (record baseline and track):

– Knee OA: WOMAC, KOOS, and pain VAS/NRS.[9][14]

– Shoulder: appropriate functional score (e.g. Constant/ASES).[2]

– Function: gait/physical performance where frailty is relevant (e.g. SPPB).[17]

Baseline investigations:

– Imaging: weight-bearing radiographs to grade OA (Kellgren–Lawrence); ultrasound/MRI for tendinopathy where indicated.

– Bloods: FBC and coagulation screen if bleeding risk; CRP/ESR if inflammatory or infective process suspected; blood-borne virus status per local processing protocol.

– No validated ageing-biomarker panel is indicated to guide these interventions; if ageing clocks are recorded for research they should be framed as exploratory surrogates with no established link to outcomes.

Risk stratification: low risk = healthy adult, mild–moderate OA, no bleeding/infection/malignancy; high risk = frailty, anticoagulation, immunosuppression, malignancy, end-stage joint — these require specialist input or avoidance.

 

6. Dosing regimens and practical implementation

ACS (regimens used in trials — modest human support):

– Whole blood drawn into proprietary syringes with glass beads, incubated (typically ~6–24 h at 37°C), centrifuged, serum aliquoted and frozen.[1]

– Intra-articular injection typically ~2 mL, once weekly for 4 (up to 6) injections, often followed by physiotherapy.[18]

– No robust dose–response data; regimens are largely empirical/manufacturer-derived.

PRP (knee OA):

– Single or a short series of 1–3 intra-articular injections; leucocyte-poor PRP commonly preferred; preparation methods vary widely and are not standardised, which is a major source of heterogeneity.[3][11]

APS / PRGF / platelet lysate: protocols are product-specific and supported only by sparse data.[2]

Regimens supported by robust human data: none for longevity endpoints. For OA symptom relief, ACS series and PRP for KL 1–3 have low-to-moderate support.[9][11][18]

Regimens requiring caution (early-phase/preclinical only): systemic or intravenous administration of MSCs, exosomes or “rejuvenation” infusions for anti-ageing — should not be offered outside trials.[5][7][8]

 

7. Monitoring, safety and follow-up

Monitoring plan:

– Clinical: injection-site reaction, effusion, pain flare, signs of septic arthritis (increasing pain, swelling, erythema, fever — urgent).

– PROMs (WOMAC/KOOS/VAS) at baseline and follow-up.[9][14]

– No specific laboratory or ageing-biomarker monitoring is validated.

Suggested timepoints: review at ~3, 6, 12 and 24 weeks for symptom response (mirroring trial endpoints); consider re-treatment only if meaningful, sustained benefit.[14][18]

Adverse effects:

– Common (mild–moderate): transient injection-site pain, swelling, stiffness — mostly self-limiting. In the ACS meta-analysis complication rates were similar to saline (ACS 24.8% vs saline 24.4%).[2][9]

– Serious but rare: septic arthritis, significant bleeding/haemarthrosis.[9]

– Action for abnormal findings: suspected joint infection → stop, aspirate, urgent orthopaedic/rheumatology referral; persistent effusion or lack of benefit → discontinue.

Interactions: anticoagulants/antiplatelets increase procedural bleeding risk; intra-articular corticosteroid may be combined with ACS in some protocols but concurrent immunosuppression warrants caution.[14]

Special populations:

– Pregnancy/breastfeeding: not indicated; avoid.

– Renal/hepatic impairment: no specific data; procedural (not pharmacokinetic) considerations dominate.

– Frailty/extremes of age: no demonstrated benefit; cell-based approaches research-only.[13]

 

8. Contraindications and cautions

Absolute:

– Active local or systemic infection / septic joint.

– Overlying cellulitis or skin breakdown at injection site.

– Uncontrolled coagulopathy.

Relative / specialist advice needed:

– Active or recent malignancy (growth-factor/cell products — theoretical concern).[3]

– Therapeutic anticoagulation or significant thrombocytopenia.

– Immunosuppression.

– End-stage OA (KL 4) — PRP inappropriate by consensus.[12]

Harm likely to outweigh benefit with current evidence:

– Use for anti-ageing/biological-age reversal, systemic “rejuvenation” infusions, and any allogeneic/exosome product outside a trial.[4][5]

 

9. Practical management scenarios (CKS-style)

Scenario A — Middle-aged patient with multiple cardiometabolic risk factors requesting “longevity” injections.

– Recommendation: Avoid for longevity indications (recommend against); consider ACS/PRP only if concurrent symptomatic KL 1–3 knee OA refractory to conservative care (conditional).

– Assessment: confirm any joint pathology; optimise modifiable cardiometabolic risk (this delivers the real longevity benefit).

– Shared decision-making: state explicitly there is no evidence these products alter ageing or cardiometabolic outcomes.[5][6]

– Initiation: if OA present, ACS series or single-course PRP.[11][18]

– Monitoring: PROMs at 3/6/12 weeks; stop if no benefit.

– Escalate/refer: orthopaedic review if progressive disease.

Scenario B — Older, frail patient with multimorbidity.

– Recommendation: Avoid outside research. No evidence of functional or survival benefit; higher procedural risk.[13]

– Prioritise evidence-based interventions: resistance exercise, protein/leucine/vitamin D optimisation, and management of osteosarcopenia.[19][17][20]

– If symptomatic joint disease, standard OA pathway and specialist input preferred.

Scenario C — Adjunct to conventional therapy in a patient already under specialist care (e.g. knee OA on physiotherapy ± steroid injection).

– Recommendation: Consider (conditional) — ACS may add to intra-articular steroid for longer symptom control based on a single small RCT; PRP is a consensus-supported option for KL 1–3, though recent data question superiority over saline.[14][11][12][15]

– Assessment: confirm KL grade, coordinate with the treating specialist.

– Consent: document off-label status, weak/conflicting evidence, and placebo-response contribution.[9]

– Initiation: ACS series or PRP per protocol.[11][18]

– Monitoring: PROMs to 24 weeks; re-treat only if sustained benefit.

– Stop/refer: no response by ~3 months → discontinue; surgical referral for progression.

 

10. Research gaps and future directions

– Definitive placebo-controlled trials: a high-quality multicentre RCT of ACS versus saline in OA is needed, given the loss of significance against placebo.[9]

– Standardisation: preparation, dosing, leucocyte content and quality control of ACS/PRP remain non-standardised and impede reproducibility.[4]

– Longevity endpoints: no human data link these products to mortality, healthspan, or validated biological-age measures; such claims rest on rodent/in-vitro work.[7][8]

– Cell/vesicle therapies: MSC and exosome anti-ageing effects require rigorous clinical trials with ageing clocks as exploratory (not primary clinical) endpoints.[8][13]

– Registries: all longevity-context use should occur within trials or registries to capture safety and outcomes.

References

1. Autologous Conditioned Serum for Degenerative Diseases and Prospects. Shakouri SK, Dolati S, Santhakumar J, Thakor AS, Yarani R. Growth Factors (Chur, Switzerland). 2021 Feb-Jul;39(1-6):59-70. doi:10.1080/08977194.2021.2012467.
2. Autologous Peripheral Blood-Derived Orthobiologics for the Management of Shoulder Disorders: A Review of Current Clinical Evidence. Gupta A, Maffulli N. Pain and Therapy. 2025;14(1):67-79. doi:10.1007/s40122-024-00684-5.
3. Current State of Platelet-Rich Plasma and Cell-Based Therapies for the Treatment of Osteoarthritis and Tendon and Ligament Injuries. Su CA, Jildeh TR, Vopat ML, et al. The Journal of Bone and Joint Surgery. American Volume. 2022;104(15):1406-1414. doi:10.2106/JBJS.21.01112.
4. An International Expert Consensus Statement Defining the Best Practices and Areas of Uncertainty Concerning the Use of Orthobiologics. Kunze KN, Morgan JT, Gerhold C, et al. The Journal of Bone and Joint Surgery. American Volume. 2026;:00004623-990000000-01938. doi:10.2106/JBJS.26.00723.
5. Mesenchymal Stem Cells and Exosomes: A Novel Therapeutic Approach for Aging. Lan D, Zhang D, Dai X, et al. Experimental Gerontology. 2025;206:112781. doi:10.1016/j.exger.2025.112781.
6. Research Progress on Blood Therapy for Anti-Aging. Liu S, Wang S, Dong Y, Yang S, Yao C. Journal of Advanced Research. 2026;82:981-998. doi:10.1016/j.jare.2025.07.039.
7. Delayed Animal Aging Through the Recovery of Stem Cell Senescence by Platelet Rich Plasma. Liu HY, Huang CF, Lin TC, et al. Biomaterials. 2014;35(37):9767-9776. doi:10.1016/j.biomaterials.2014.08.034.
8. Mesenchymal Stem Cells and Their Derivatives as Potential Longevity-Promoting Tools. Rudnitsky E, Braiman A, Wolfson M, et al. Biogerontology. 2025;26(3):96. doi:10.1007/s10522-025-10240-z.
9. Is There a Role For autologous Conditioned Serum injections In osteoarthritis? A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Curtis A, Beswick A, Jenkins L, Whitehouse M. Osteoarthritis and Cartilage. 2024;32(10):1197-1206. doi:10.1016/j.joca.2024.06.004.
10. Autologous Interleukin 1 Receptor Antagonist Blood-Derived Products for Knee Osteoarthritis: A Systematic Review. Ajrawat P, Dwyer T, Chahal J. Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2019;35(7):2211-2221. doi:10.1016/j.arthro.2018.12.035.
11. The Use of Injectable Orthobiologics for Knee Osteoarthritis: A European ESSKA-ORBIT Consensus. Part 1-Blood-Derived Products (Platelet-Rich Plasma). Laver L, Filardo G, Sanchez M, et al. Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA. 2024;32(4):783-797. doi:10.1002/ksa.12077.
12. Platelet-Rich Plasma Injections for the Management of Knee Osteoarthritis: The ESSKA-ICRS Consensus. Recommendations Using the RAND/UCLA Appropriateness Method for Different Clinical Scenarios. Kon E, de Girolamo L, Laver L, et al. Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA. 2024;32(11):2938-2949. doi:10.1002/ksa.12320.
13. Attenuation of Frailty in Older Adults With Mesenchymal Stem Cells. Florea V, Bagno L, Rieger AC, Hare JM. Mechanisms of Ageing and Development. 2019;181:47-58. doi:10.1016/j.mad.2019.111120.
14. Intra-Articular Autologous Conditioned Serum and Triamcinolone Injections in Patients With Knee Osteoarthritis: A Controlled, Randomized, Double-Blind Study. Damjanov N, Zekovic A. The Journal of International Medical Research. 2023;51(10):3000605231203851. doi:10.1177/03000605231203851.
15. Osteoarthritis. Kloppenburg M, Namane M, Cicuttini F. Lancet (London, England). 2025;405(10472):71-85. doi:10.1016/S0140-6736(24)02322-5.
16. Autologous Blood and Platelet-Rich Plasma Injection Therapy for Lateral Elbow Pain. Karjalainen TV, Silagy M, O’Bryan E, et al. The Cochrane Database of Systematic Reviews. 2021;9:CD010951. doi:10.1002/14651858.CD010951.pub2.
17. Biological Basis and Treatment of Frailty and Sarcopenia. Sato R, Vatic M, Peixoto da Fonseca GW, Anker SD, von Haehling S. Cardiovascular Research. 2024;120(9):982-998. doi:10.1093/cvr/cvae073.
18. Treatment of Osteoarthritis of the Knee With a Combination of Autologous Conditioned Serum and Physiotherapy: A Two-Year Observational Study. Baselga García-Escudero J, Miguel Hernández Trillos P. PloS One. 2015;10(12):e0145551. doi:10.1371/journal.pone.0145551.
19. The Effect of Β-Hydroxy-Β-Methylbutyrate (HMB) on Sarcopenia and Functional Frailty in Older Persons: A Systematic Review. Oktaviana J, Zanker J, Vogrin S, Duque G. The Journal of Nutrition, Health & Aging. 2019;23(2):145-150. doi:10.1007/s12603-018-1153-y.
20. Why Osteosarcopenia Matters: Clinical and Investigative Implications. Bonamigo EL, Maia MN, Pinheiro Cavallaro de Oliveira R, et al. European Journal of Clinical Investigation. 2026;56(5):e70221. doi:10.1111/eci.70221.